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Washington, DCFigure 1. Survival by Original HLA Match.The therapeutic use of T cells has long been studied to
boost HIV-speciﬁc T-cell immunity in HIV+ individuals.
However, clinical efﬁcacy has been relatively modest.
Infusion of single-epitope speciﬁc CD8 T cells showed safety
but could not provide lasting viral control, most likely due
to their restricted speciﬁcity. Recently, the development of
HIV entry resistant cells by other groups (e.g. CCR5 deletion)
has allowed T cell therapy to be even more feasible for HIV.
We hypothesized that broadly HIV-speciﬁc T cells could be
expanded from patients on antiretrovirals (ARVs) as well as
HIV negative individuals to effectively target HIV infection
using a non-HLA restricted approach for patients receiving
an autologous or allogeneic HSCT for HIV-associated
hematologic diseases. PBMCs from healthy donors or
HIV+ patients were stimulated with gag, pol, and nef pep-
tide libraries (pepmixes) in the presence of co-stimulatory
and growth factors. T cells expanded to clinically relevant
numbers (Mean¼1.62e8 cells, Range¼3.72e7-2.87e8 cells,
n¼7) even in the presence of ARVs. 5 of 7 patient sample
lines showed speciﬁc activity to all 3 HIV antigens in IFNY
ELISPOT assays. The T cells were broadly speciﬁc to gag
(99.33 SFC/10e5 cells), pol (131.11 SFC) and nef (337.26 SFC).
HIV-speciﬁc T cells were also expanded from 9 healthy (HIV
negative) donors. Expanded T cells released IFNg in
response to gag (163.79 SFC, n¼9) and nef (291.25 SFC, n¼6)
but not an irrelevant antigen (7.0 SFC). Importantly, T cells
expanded from both HIV+ and HIVneg were cytotoxic, as
expanded T cells lysed HIV antigen loaded autologous PHA
blasts (mean¼67.55% speciﬁc lysis at 10:1 effector:target
ratio) but not PHA blasts alone (0.46% speciﬁc lysis at 10:1
effector target ratio). Expanded T cells from HIV+ patients
also showed a greater ability to suppress HIV outgrowth in
vitro compared to unexpanded CD8+ T cells when
co-cultured with autologous, reactivated resting CD4+ T
cells, the authentic latent reservoirs. In 5 patients, a lower
recovery of virus from resting CD4+ cells was seen in the
presence of CTLs as compared to no effectors (p<0.006 by
Mann Whitney), while the non-speciﬁc CD8+ T-cells
showed only a modest trend towards decreased recovery
(p>0.9). Similarly, HIV-speciﬁc T cells derived from HIVneg
donors were able to suppress HIV replication more than
non-speciﬁc CD8+ T-cells when co-cultured with autolo-
gous CD4+ T cells infected with HIVSF162 (HIV only
p24¼681.95 pg/mL, nonspeciﬁc CD8+ T-cells¼448.80 pg/
mL, expanded CTL¼145.82 pg/mL). In summary, we have
developed robust GMP-compliant methodology for
expanding functional HIV-speciﬁc T cells from both HIV+
and HIVneg donors for use after autologous and allogeneic
HSCT, respectively. We now plan to translate our approach
to the clinical setting where we will test HIV-polyspeciﬁc T
cell products as a part of a strategy to fully eradicate HIV
infection after HSCT.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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Background: Current practice in choosing potential donors
for umbilical cord blood transplantation (UCBT) involves
matching at the antigen level for HLA-A and HLA-B by
low-resolution (LR) typing and at the allele level for
HLA-DRB1 by high-resolution (HR) typing.
Objectives: To determine the signiﬁcance of HR HLA
matching on UCBT outcome in 62 eligible pediatric patients
<¼21 years-of-age. We further explored the presence of
anti-HLA antibodies (AHA) in our patient population.
Design/Method: Through IRB approved retrospective chart
review, we identiﬁed 62 UCBT recipients (>¼2.0X10 ˇ7TNC/
kg) for malignant (53%) and non-malignant (47%) disorders.
We compared original HLA typing (LR HLA-A-B; HR
HLA-DRB1) to HR HLA typing (HR HLA-A-B-C-DRB1). We
determined incidence of engraftment, relapse, acute and
chronic graft-versus-host disease (GVHD), early transplant-
related infections and mortality (from any cause and non-
relapse/non-disease progression mortality) and analyzed
each of these variables against subgroups of HR and
original HLA matching using the Fisher exact test. Lastly, we
determined the presence of pre-UCBT AHA.
Results: Retrospective determination of HR HLA matching
showed 16% of pairs were matched at all HR loci; 6% were
mismatched at 1,14% at 2, 29% at 3, 27% at 4, 3% at 5, and 2% at
both 6 and 7 alleles. Ten of 13 (77%) transplants originally
matched at LR HLA-A-B and HR HLA-DRB1 remained
matched at the allelic level (HR HLA-A-B-C-DRB1).
Figure 2. Survival by Retrospective High Resolution HLA Match.
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>¼5/8, <6/8 vs >¼6/8 allelic matches) showed signiﬁcant
reduction in mortality from any cause and non-relapse/
non-disease progression mortality in transplants matched at
>¼6/8 versus <6/8 alleles (p ¼ 0.02 and 0.01, respectively).
Although decreased in incidence, there was no signiﬁcant
association for graft failure, GVHD or infections. In subgroup
comparison using original HLA typing (<3/6 vs >¼3/6, <4/6
vs>¼4/6,<5/6 vs>¼5/6 matches), a signiﬁcant reduction in
mortality from any cause and non-relapse/non-disease
progression mortality was seen in those matched at >¼5/6
versus <5/6 loci (p¼0.05 and 0.01, respectively). Screening
for class I and II AHA was available in 27 patients and was
positive in 8/14 patients with primary graft failure and 3/13
who engrafted. Results were not available for 30/43
engrafters and 5/19 non-engrafters.
Conclusion: HR typing showed an increase in HLA recipient
cord disparity in comparison to standard typing. We
validated the current standard for UCB selection as >¼5/6
grafts were associated with signiﬁcantly improved overall
survival (see Figure 1), which was shown in our >¼6/8 HR
matches as well (see Figure 2). The role of AHA in graft
failure needs to be further tested. In choosing donors for
UCBT, we recommend choosing >¼6/8 HR match especially
when >¼5/6 UCB grafts are available and if able, taking
into account AHA.51
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Out of an estimated 20,000 patients requiring an alloge-
neic HCT in India, only 500 odd patients receive one. Keeping
in cognizance the resource constraints, the major reason for
the discordance lies in the lack of alternate donors. Whilst
unrelated donor marrow and cord sufﬁce for the ethnicmajorities in Europe and the USA, such registries provide for
less than 10% of HCT recipients due to both cost and an
available match. With this background, we initiated a
Haploidentical Family Donor HCT program in 2011.
In our initial screening of 50 patients referred for an
allogeneic BMT, a matched family donor was available in 11
patients and a suitable Haploidentical family donor was
available for 49, whereas a fully matched unrelated donor
(10/10) was available for none. Hence we decided to develop
a Haploidentical BMT program within the available
resources. We chose a Posttransplant Cyclophosphamide
(PTCY) based approach with PBSC as the graft source.
We have carried out 40 transplants in 32 patients over the
last 3 years (AML-15; ALL-2; CML-BC-2; Lymphoma-2;
Severe Aplastic Anemia (SAA)-10; Thalassemia-1). All
received PBSC with PTCY on days 3 and 4 followed by
cyclosporine and MMF. The conditioning regimen comprised
of Fludarabine 150 mg/CY-30 mg/Melphalan-100 mg (SAA)
or 120-140 mg (others) with Fludarabine and IV Busulfan
(6.4-9.6 mg/kg) or Treosulfan 10-12 gm/m2. 2GY TBI was
offered to 4 patients instead of Melphalan. Sirolimus
was added later on day -7 pretransplant to the last 5 patients
with SAA.
30/32 patients surviving beyond 21 days had successful
engraftment with full donor chimerism, including 10/11 pa-
tients with SAA and Thalassemia. 6/8 evaluable patients un-
dergoing a second Haploidentical HCT engrafted as well.
Acute GVHD grade 2-4 developed in 3/32 patients. Day 100
NRM was 5/32 (15%) and the overall survival at 2 years
was 55%. The major cause of NRM was infection with
Carbapenem-resistant Gram Negative Bacilli accounting for
90% of the deaths. Chronic GVHD occurred in 10% of the
evaluable patients. With stringent monitoring for CMV and
preemptive therapy, only 1 patient succumbed to CMV
disease. The outcome and cost of this extremely high risk
group of patients were comparable to matched family donor
BMT. PBSC as graft sourcewas associatedwith a low incidence
of both acute and chronic GVHD.We also studied the effect of
Natural Killer Cell Ligand Mismatch (NKLMM) donor on the
outcome in all our patients. NKLMM was associated with
reduced incidence of relapse in patients with hematological
malignancies (p¼0.03). However, NKLMM donor was asso-
ciated with poor outcome in patients with SAA (p¼0.05).
In summary, Haploidentical HCT based on PTCY and PBSC
graft is feasible and probably the most viable form of
alternate donor HCT in resource constrained settings with
outcomes comparable to matched donor HCT.52
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Background: Mismatched unrelated donor (MMURD)
transplantation is widely used in patients who lack a
matched unrelated donor (MUD). Despite several published
observational studies, the magnitude of risk associated with
9 out of 10 MMURD transplant and that of HLA-speciﬁc
mismatches is still unclear. We performed a meta-analysis to
